ClinicalTrials.gg
CompletedNCT00351403Updated Feb 8, 2010

Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection

A Phase 4 interventional study of Ribavirin and Peginterferon alfa 2b in Hepatitis C, Chronic, sponsored by FGK Clinical Research GmbH. Completed at 22 sites in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2010-02-08.

Sponsored by FGK Clinical Research GmbH · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
390
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 175 studies testing ribavirin in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. Ribavirin · Hepatitis C, Chronic.

Planned enrollment
34th of 174
390 · median 107
Started
2006
with 14 others
Phase 4
55 of 175
none open now
Registered
42nd of 175
by date

Among the 175 studies testing ribavirin in Hepatitis C, Chronic, this one is the 34th largest by planned enrollment of the 174 interventional ones that give a count, is one of 15 that started in 2006, is one of 55 in phase 4, and was the 42nd registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 175 studies testing ribavirin in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About ribavirin

Ribavirin: first FDA approval 1985 (VIRAZOLE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 175 studies testing ribavirin in Hepatitis C, Chronic as a file.
02

Study summary

Patients with chronic hepatitis C genotype 1 virus infection are usually treated with Interferon alfa plus Ribavirin over 48 weeks. For some patients this might be too long, for others too short. An individually adapted therapy length from 24 to 72 weeks will be determined in dependence of the initial virus load and the time to HCV RNA negativity.

The primary objective is to compare the cumulative rate of the sustained viral response (SVR) of the patients with the individually adapted therapy duration to the SVR rates of a historic patient collective under the 48 week standard therapy.

Read the detailed description

Further objectives of this trial are:

To record the tolerance of the therapy with Peginterferon alfa-2b plus Ribavirin over 72 weeks inclusive the adverse reactions and the withdrawal rates.

To evaluate the biochemical response to the treatment (ALT values during and after the therapy) in comparison to the virological response to the treatment.

To evaluate the validity of the withdrawal rules of this trial at week 12 and 24 in comparison to the 2-log-rule and a qualitative detection of the HCV RNA at week 24 with a detection limit of 50 IU/ml.

To evaluate the impact of the HCV RNA concentration before the therapy, and the HCV kinetic during the therapy on the response to the treatment in the different groups.

To evaluate the impact of the serum concentration of Ribavirin on anaemia and the virological therapy response, as well as the dependence of the serum concentration of Ribavirin on the creatinine clearance in comparison to the body weight.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

Keywords

  • Chronic HCV infection
  • Genotype 1
  • Individually adapted therapy
  • Peginterferon alfa-2b
  • Ribavirin
  • Sustained viral response (SVR)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients with a chronic infection (HCV antibodies and HCV RNA positive)
  • Presence of a HCV genotype 1 infection
  • Presence of a compensated liver disease satisfying following hematological and biochemical minimum criteria: - value >= 13 g/dl in men, >= 12 g/dl in women - Leukocytes >= 3.000/mm3 or neutrophile granulocytes > 1.500/mm3 - > 80.000/mm3
  • Total in the normal range
  • Albumin in the normal range
  • Serum creatinine in the normal range THS in the normal range
  • Exclusion of an hepatitis
  • Alpha-Fetoprotein in the normal range
  • Negative test
  • Negativity of surface antigens (Hbs-Ag)
  • Normal or elevated /GTP values at screening
  • At known diabetes mellitus or hypertension an ophthalmologic examination must be performed
  • Liver within the last 12 months must confirm the diagnoses of a chronic hepatitis
  • A confirmation must be given that sexually active patients practice a save method of during the therapy and 6 (women) to 7 (men) months after the therapy

Exclusion Criteria:

  • Age \< 18 years, > 70 years
  • Previous treatment of hepatitis c with (Peg)Interferon alfa or (Peg)Interferon alfa/Ribavirin
  • Patients with organ transplantations other than cornea or hair
  • Infection with HCV genotype 2,3,4,5 or 6
  • Pregnant or nursing women
  • Any other reason for the liver disease than chronic hepatitis C
  • Suspected to Interferon, Peginterferon or Ribavirin
  • Participation in a clinical trial or treatment with an product 30 days before inclusion in this study
  • Patients with any kind of hemoglobinopathy
  • Documented liver disease in advanced state Liver cirrhosis Child B and C
  • Each known and existing clinical conditions that might challenge the participation or completion of this clinical trial as depressions, psychosis, severe psychiatric diseases, suicide ideations CNS traumata or cramps which need medicamentous treatment
  • Relevant cardiovascular dysfunctions in the last 6 months or patients with changes in the
  • Insufficiently adjusted diabetes mellitus
  • Severe chronic lung diseases (as e.g. )
  • Immunologic diseases or autoimmune-diseases or any other disease which demand a longtime treatment with during this clinical trial
  • Clinically relevant gout
  • Abuse of drugs, alcohol or pharmaceuticals
  • Patient with clinically relevant changes of the retina
  • Missing ability or willingness to understand the purpose of this study or to give a written consent for participating in this study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
390 participants (estimated)

Study arms

  • Experimental
    Individualized therapy

    Lengh of therapy depends on time point when no HCV RNA is detectable in blood with Versant HCV Qualitative assay.

    Drug: Ribavirin · Drug: Peginterferon alfa 2b

  • Other
    Historical control

    48 week standard therapy

    Drug: Ribavirin · Drug: Peginterferon alfa 2b

Interventions

06

What researchers measure

Primary outcomes

  1. Sustained viral response (HCV RNA negativity 24 weeks after end of treatment)

07

Study locations

22 sites
  • Medizinische Universitätsklinik Freiburg
    Freiburg, Baden-Württemberg 79106, Germany
  • Universitätsklinik Heidelberg
    Heidelberg, Baden-Württemberg 69120, Germany
  • Universitätsklinikum Ulm
    Ulm, Baden-Württemberg 89081, Germany
  • Uniklinikum Erlangen
    Erlangen, Bayern 91056, Germany
  • Klinikum Großhadern
    München, Bayern 81377, Germany
  • Technische Universität München
    München, Bayern 81675, Germany
  • Klinikum der Universität Würzburg
    Würzburg, Bayern 97080, Germany
  • Klinikum der J.W.-Goethe-Universität
    Frankfurt, Hessen 60590, Germany
  • Praxis für Innere Medizin
    Frankfurt, Hessen 60596, Germany
  • Medizinische Hochschule Hannover
    Hannover, Niedersachsen 30625, Germany
  • St. Josef-Hospital
    Bochum, Nordrhein-Westfalen 44791, Germany
  • Gemeinschaftspraxis
    Dusseldorf, Nordrhein-Westfalen 40237, Germany
  • Medizinische Universitäts-Klinik Essen
    Essen, Nordrhein-Westfalen 45122, Germany
  • Universität zu Köln
    Köln, Nordrhein-Westfalen 50924, Germany
  • Universitätsklinikum Aachen
    Aachen, Nordrhein.Westfalen 52074, Germany
  • Universitätsklinikum der J. Gutenberg Universität
    Mainz, Rheinland-Pfalz 55131, Germany
  • Universitätsklinikum des Saarlandes
    Homburg / Saar, Saarland 66421, Germany
  • Universitätsklinikum Leipzig
    Leipzig, Sachsen 04103, Germany
  • Christian-Albrechts-Universität zu Kiel
    Kiel, Schleswig-Holstein 24105, Germany
  • Hepatologische Schwerpunktpraxis
    Berlin, 10969, Germany
  • Charité, Campus Virchow-Klinikum
    Berlin, 13353, Germany
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
08

References and documents

Publications

  • Sarrazin C, Schwendy S, Moller B, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Prinzing R, Herrmann E, Zeuzem S, Berg T. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology. 2011 Nov;141(5):1656-64. doi: 10.1053/j.gastro.2011.07.019. Epub 2011 Jul 22. PubMed 21784046 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2006
First posted
Jul 12, 2006
Start
Jul 2006
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Last update
Feb 8, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00351403
Lead sponsor
FGK Clinical Research GmbH
Collaborators
University Hospital, Saarland
First posted
Jul 12, 2006
Start date
Jul 2006
Primary completion
Jan 2010
Completion
Jan 2010
Last update
Feb 8, 2010

Study contacts

Christoph Sarrazin, MD, PhD
study chair · University Hospital, Saarland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ribavirin · Peginterferon alfa-2b

Start the discussion